article thumbnail

FDA Inspections: Lesson 1 – Interviewing Employees

FDA Law Blog: Biosimilars

As part of the Food and Drug Administration Safety and Innovation Act (known as FDASIA) and later under the FDA Reauthorization Act of 2017 (known as FDARA), a drug or medical device can be deemed adulterated if a regulated company delays, denies, or limits an inspection, or refuses to permit an entry or inspection.

FDA 105
article thumbnail

Achieving IVDR certification that meets EU regulation in 2022

Tecan

By Günter Weisshaar The announcement of the In Vitro Diagnostics Regulation (IVDR) in 2017 was celebrated as an essential upgrade to in vitro diagnostic (IVD) device regulations in Europe. It came into force in May 2017, with a five-year transition period that was initially proposed to finish on May 26, 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. This approach augments the strength of achieving immune homeostasis.

Disease 52
article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

FDA Law Blog: Biosimilars

Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). This guidance, when finalized, will replace the original version of this document finalized in 2017. By Jeffrey N.

FDA 111
article thumbnail

AgencyIQ Guidance Tracker: European medical device and diagnostics guidance documents

Agency IQ

BY COREY JASEPH, MS, RAC With the many moving parts of the European medical device and IVD regulations, it can be difficult to keep up on planned guidance and other publications, published documents and document revisions. Our new resource aims to help make this a little bit easier.

article thumbnail

A Long Time Coming: DEA Regs Finally Authorize Schedule II Prescription Partial Fills

FDA Law Blog: Biosimilars

Three years after that letter, DEA proposed a rule to amend its regulations consistent with CARA on December 20, 2020. Now, in July 2023, DEA has finally issued its final rule amending its regulations for partial filling of prescriptions for schedule II substances. 78,282 (Dec.

article thumbnail

The internal clock of our cells is influenced by mechanical forces

SCIENMAG: Medicine & Health

This internal clock regulates vital physiological processes including sleep, metabolism, hormonal fluctuations, body temperature, and blood pressure. In 2017, the Nobel Prize in Medicine was bestowed upon researchers who made significant breakthroughs in […]